Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
O Kyu Noh 3 Articles
Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG)
Jun Eun Park, O Kyu Noh, Yonghee Lee, Hyoung Soo Choi, Jung Woo Han, Seung Min Hahn, Chuhl Joo Lyu, Ji Won Lee, Keon Hee Yoo, Hong Hoe Koo, Seon-Yong Jeong, Ki Woong Sung
Cancer Res Treat. 2020;52(2):438-445.   Published online September 10, 2019
DOI: https://doi.org/10.4143/crt.2019.313
AbstractAbstract PDFPubReaderePub
Purpose
Loss of heterozygosity (LOH) at chromosomes 1p and 16q is a poor prognostic factor in favorable histology Wilms tumor (FHWT). This study investigated the prevalence of LOH at 1p and 16q and evaluated its prognostic value in Korean children with FHWT. Materials and Methods We analyzed 101 FHWT patients who were diagnosed between 1996 and 2016 in Korean Society of Pediatric Hematology Oncology Group hospitals. Using paraffin-embedded kidney tissue samples sent from each center, we reviewed LOH at 1p and 16q in each patient and assessed the prognostic value of LOH status for clinical parameters affecting event-free survival (EFS).
Results
Of the 101 patients, 12 (11.9%) experienced recurrence; the 3-year EFS was 87.6%. LOH at 1p or 16q was detected in 19 patients (18.8%), with five having LOH at both 1q and 16q. The frequency of LOH at 1p was higher among younger patients (p=0.049), but there was no difference in LOH prevalence according to tumor stage. In the multivariate analysis, LOH at 16q was a significant negative prognostic factor affecting EFS (3-year EFS, 73.7% vs. 91.1%; hazard ratio, 3.95; p=0.037), whereas LOH at 1p was not (p=0.786). Conclusion LOH at 16q was a significant negative prognostic factor affecting outcome in Korean pediatric FHWT patients. Due to the small sample size of this study, large-scale multicenter trials are warranted to investigate the prognostic value of LOH at 1p and 16q in Korean children with FHWT.

Citations

Citations to this article as recorded by  
  • Loss of heterozygosity for chromosomes 16q in Wilms tumors predicts outcomes: A meta-analysis
    Yuan-Hua Song, Wen-Ling Li, Zhen Yang, Yan Gao, Zhi-Ping Feng
    World Journal of Gastrointestinal Oncology.2024; 16(5): 2159.     CrossRef
  • Inter-Ethnic Variations in the Clinical, Pathological, and Molecular Characteristics of Wilms Tumor
    Kia Teng Lim, Amos H. P. Loh
    Cancers.2024; 16(17): 3051.     CrossRef
  • Epidemiologic and Clinical Outcomes of Pediatric Renal Tumors in Korea: A Retrospective Analysis of The Korean Pediatric Hematology and Oncology Group (KPHOG) Data
    Kyung-Nam Koh, Jung Woo Han, Hyoung Soo Choi, Hyoung Jin Kang, Ji Won Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Kyung Taek Hong, Jung Yoon Choi, Sung Han Kang, Hyery Kim, Ho Joon Im, Seung Min Hahn, Chuhl Joo Lyu, Hee-Jo Baek, Hoon Kook, Kyung Mi Pa
    Cancer Research and Treatment.2023; 55(1): 279.     CrossRef
  • Research Advances of Prognostic Risk Factors of Wilms Tumor
    建宇 汪
    World Journal of Cancer Research.2023; 13(02): 51.     CrossRef
  • Current Challenges of Asian National Children's Cancer Study Groups on Behalf of Asian Pediatric Hematology and Oncology Group
    Chi-kong Li, Purna Kurkure, Ramandeep Singh Arora, Bow Wen Chen, Kirill Kirgizov, Yasuhiro Okamoto, Panya Seksarn, Yongmin Tang, Keon Hee Yoo, Bharat Agarwal, Godfrey C.F. Chan, Rashmi Dalvi, Hiroki Hori, Muhammad Saghir Khan, Alice Yu, Akira Nakagawara
    JCO Global Oncology.2023;[Epub]     CrossRef
  • 6,422 View
  • 252 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Dummy Run of Quality Assurance Program before Prospective Study of Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases from Non-small Cell Lung Cancer: Korean Radiation Oncology Group (KROG) 17-06 Study
Eunah Chung, Jae Myoung Noh, Kyu Chan Lee, Jin Hee Kim, Weon Kuu Chung, Yang-Gun Suh, Jung Ae Lee, Ki Ho Seol, Hong Gyun Wu, Yeon Sil Kim, O Kyu Noh, Jae Won Park, Dong Soo Lee, Jihae Lee, Young Suk Kim, Woo-Yoon Park, Min Kyu Kang, Sunmi Jo, Yong Chan Ahn
Cancer Res Treat. 2019;51(3):1001-1010.   Published online October 15, 2018
DOI: https://doi.org/10.4143/crt.2018.415
AbstractAbstract PDFPubReaderePub
Purpose
Lung Cancer Subcommittee of Korean Radiation Oncology Group (KROG) has recently launched a prospective clinical trial (KROG 17-06) of hippocampus-sparing whole brain radiotherapy (HS-WBRT) with simultaneous integrated boost (SIB) in treating multiple brain metastases from non-small cell lung cancer. In order to improve trial quality, dummy run studies among the participating institutions were designed. This work reported the results of two-step dummy run procedures of the KROG 17-06 study.
Materials and Methods
Two steps tested hippocampus contouring variability and radiation therapy planning compliance. In the first step, the variation of the hippocampus delineation was investigated for two representative cases using the Dice similarity coefficients. In the second step, the participating institutions were requested to generate a HS-WBRT with SIB treatment plan for another representative case. The compliance of the treatment plans to the planning protocol was evaluated.
Results
In the first step, the median Dice similarity coefficients of the hippocampus contours for two other dummy run cases changed from 0.669 (range, 0.073 to 0.712) to 0.690 (range, 0.522 to 0.750) and from 0.291 (range, 0.219 to 0.522) to 0.412 (range, 0.264 to 0.598) after providing the hippocampus contouring feedback. In the second step, with providing additional plan priority and extended dose constraints to the target volumes and normal structures, we observed the improved compliance of the treatment plans to the planning protocol.
Conclusion
The dummy run studies demonstrated the notable inter-institutional variability in delineating the hippocampus and treatment plan generation, which could be decreased through feedback from the trial center.

Citations

Citations to this article as recorded by  
  • Radiotherapy trial quality assurance processes: a systematic review
    Chloe Brooks, Elizabeth Miles, Peter J Hoskin
    The Lancet Oncology.2024; 25(3): e104.     CrossRef
  • Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer
    Sehhoon Park, Jae Myoung Noh, Yoon-La Choi, Sang Ah Chi, Kyunga Kim, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
    European Journal of Cancer.2022; 169: 42.     CrossRef
  • Region-Specific Effects of Fractionated Low-Dose Versus Single-Dose Radiation on Hippocampal Neurogenesis and Neuroinflammation
    Zoé Schmal, Claudia E. Rübe
    Cancers.2022; 14(22): 5477.     CrossRef
  • Non–coplanar whole brain radiotherapy is an effective modality for parotid sparing
    Jaehyeon Park, Jae Won Park, Ji Woon Yea
    Yeungnam University Journal of Medicine.2019; 36(1): 36.     CrossRef
  • 8,714 View
  • 280 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer
Jaesung Heo, Mison Chun, O Kyu Noh, Young-Taek Oh, Kwang Wook Suh, Jun Eun Park, Oyeon Cho
Cancer Res Treat. 2016;48(1):232-239.   Published online March 13, 2015
DOI: https://doi.org/10.4143/crt.2014.351
AbstractAbstract PDFPubReaderePub
Purpose
The objective of this study was to explore the relationship between the circulating lymphocyte level during preoperative chemoradiotherapy (CRT) and pathologic complete response (pCR) in locally advanced rectal cancer.
Materials and Methods
From May 2010 to May 2013, 52 patients treated with preoperative CRT followed by surgery, were analysed. Patients received conventional fractionated radiotherapy (50-54 Gy) with fluorouracil-based chemotherapy. Surgical resection was performed at 4 to 8 weeks after the completion of preoperative CRT. Absolute blood lymphocyte counts and their relative percentage in total white blood cell counts were obtained from complete blood count tests performed prior to and after 4, 8, and 12 weeks of CRT. We analysed the association between achieving pCR and change in blood lymphocyte level during CRT, as well as clinical parameters.
Results
Among 52 patients, 14 (26.9%) had evidence of pCR. Sustaining the blood lymphocyte count during CRT (lymphocyte count at 4 weeks/baseline lymphocyte count > 0.35; odds ratio, 8.33; p=0.02) and initial carcinoembryonic antigen < 4.4 ng/mL (odds ratio, 6.71; p=0.03) were significantly associated with pCR in multivariate analyses.
Conclusion
Sustaining blood lymphocyte count during preoperative CRT was predictive for pCR in rectal cancer. Further studies are warranted to investigate the association between pathologic responses and circulating lymphocyte count with its subpopulation during preoperative CRT.

Citations

Citations to this article as recorded by  
  • Promises and Challenges of Predictive Blood Biomarkers for Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy
    Joao Victor Machado Carvalho, Valérie Dutoit, Claudia Corrò, Thibaud Koessler
    Cells.2023; 12(3): 413.     CrossRef
  • Can lymphocytes serve as a predictor of response to preoperative chemoradiation therapy for locally advanced rectal cancer?
    Myroslav Lutsyk, Tarek Taha, Salem Billan
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Severe lymphopenia as a prognostic factor in rectal cancer patients receiving adjuvant chemoradiotherapy: a retrospective study
    Shuang Li, Weiping Yao, Ruiqi Liu, Yanwei Lu, Haibo Zhang, Xiaodong Liang
    Scientific Reports.2023;[Epub]     CrossRef
  • Impact of Platelets to Lymphocytes Ratio and Lymphocytes during Radical Concurrent Radiotherapy and Chemotherapy on Patients with Nonmetastatic Esophageal Squamous Cell Carcinoma
    Yaotian Zhang, Ning Han, Xue Zeng, Chaonan Sun, Shichen Sun, Xinchi Ma, Yanyu Zhang, Zhuang Liu, Zilan Qin, Hong Guo, Yubing Li, Na Zhang, Bruno Vincenzi
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Predicting stage ypT0–1N0 for nonradical management in patients with middle or low rectal cancer who undergo neoadjuvant chemoradiotherapy: a retrospective cohort study
    Jeehye Lee, In Jun Yang, Jung Wook Suh, Hong-min Ahn, Heung-Kwon Oh, Duck-Woo Kim, Young-Hoon Kim, Kyoung Ho Lee, Sung-Bum Kang
    Annals of Surgical Treatment and Research.2022; 103(1): 32.     CrossRef
  • Histopathological and Haemogram Features Correlate with Prognosis in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation without Pathological Complete Response
    Yu-Ming Huang, Hsi-Hsien Hsu, Chien-Kuo Liu, Ching-Kuo Yang, Po-Li Tsai, Tzu-Yin Tang, Shih-Ming Hsu, Yu-Jen Chen
    Journal of Clinical Medicine.2022; 11(17): 4947.     CrossRef
  • The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non–Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors
    Xiaoyan Sun, Yingnan Feng, Bin Zhang, Wuhao Huang, Xiaoliang Zhao, Hua Zhang, Dongsheng Yue, Changli Wang
    Cancer Research and Treatment.2022; 54(4): 1017.     CrossRef
  • Predicting Factors of Complete Pathological Response in Locally Advanced Rectal Cancer
    AmirHossein Latif, Mohammad Shirkhoda, Mohammad Reza Rouhollahi, Saeed Nemati, Seyed Hossein Yahyazadeh, Kazem Zendehdel, Ahmad Reza Soroush, Aidin Yaghoobi Notash
    Middle East Journal of Digestive Diseases.2022; 14(4): 443.     CrossRef
  • Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes
    Hui Xu, Maosheng Lin, Yingying Hu, Li Zhang, Qiaoqiao Li, Jinhan Zhu, Shi Wang, Mian Xi
    The Oncologist.2021; 26(3): e425.     CrossRef
  • Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers
    Yingjia Wu, Jinbin Chen, Lei Zhao, Qiaoqiao Li, Jinhan Zhu, Hong Yang, Suping Guo, Mian Xi
    Cancer Research and Treatment.2021; 53(1): 172.     CrossRef
  • Low Lymphocyte Count Is Associated With Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients
    Xin Wang, Zongxing Zhao, Peiliang Wang, Xiaotao Geng, Liqiong Zhu, Minghuan Li
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Dose–volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer
    Łukasz Kuncman, Konrad Stawiski, Michał Masłowski, Jakub Kucharz, Jacek Fijuth
    Strahlentherapie und Onkologie.2020; 196(11): 998.     CrossRef
  • Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer
    Chinock Cheong, Jun Sang Shin, Kwang Wook Suh
    World Journal of Gastroenterology.2020; 26(44): 7022.     CrossRef
  • Lymphocyte nadir predicts tumor response and survival in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: Immunologic relevance
    Hao Liu, Hao Wang, Jianhua Wu, Yiming Wang, Liying Zhao, Guoxin Li, Meijuan Zhou
    Radiotherapy and Oncology.2019; 131: 52.     CrossRef
  • Prognostic impact of persistent lower neutrophil-to-lymphocyte ratio during preoperative chemoradiotherapy in locally advanced rectal cancer patients: A propensity score matching analysis
    Yoon Jin Cha, Eun Jung Park, Seung Hyuk Baik, Kang Young Lee, Jeonghyun Kang, Aamir Ahmad
    PLOS ONE.2019; 14(3): e0214415.     CrossRef
  • Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy
    Qiaoqiao Li, Sha Zhou, Shiliang Liu, Songran Liu, Hong Yang, Lei Zhao, Mengzhong Liu, Yonghong Hu, Mian Xi
    Annals of Surgical Oncology.2019; 26(9): 2882.     CrossRef
  • Pretreatment Blood Biomarkers Predict Pathologic Responses to Neo-Crt in Patients with Locally Advanced Rectal Cancer
    Aijie Li, Kewen He, Dong Guo, Chao Liu, Duoying Wang, Xiangkui Mu, Jinming Yu
    Future Oncology.2019; 15(28): 3233.     CrossRef
  • Association of pre-surgery to pre-radiotherapy lymphocyte counts ratio with disease-free survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy
    Hongen Xu, Guangxian You, Minjun Zhang, Tao Song, Haibo Zhang, Jia Yang, Yongshi Jia, Jianming Tang, Xiaodong Liang
    World Journal of Surgical Oncology.2019;[Epub]     CrossRef
  • Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy
    Xi-Lei Zhou, Wei-Guo Zhu, Zhi-Jian Zhu, Wan-Wei Wang, Xue Deng, Wei-Jing Tao, Fu-Zhi Ji, Yu-Suo Tong
    The Oncologist.2019; 24(8): e677.     CrossRef
  • LMR predicts outcome in patients after preoperative chemoradiotherapy for stage II-III rectal cancer
    Shinya Abe, Kazushige Kawai, Hiroaki Nozawa, Keisuke Hata, Tomomichi Kiyomatsu, Teppei Morikawa, Toshiaki Watanabe
    Journal of Surgical Research.2018; 222: 122.     CrossRef
  • Biomarqueurs inflammatoires et immunologiques de réponse à la radiothérapie
    J.P. Nesseler, D. Schaue, W.H. McBride, P. Nickers
    Cancer/Radiothérapie.2018; 22(2): 180.     CrossRef
  • Absolute Lymphocyte Count in Preoperative Chemoradiotherapy for Rectal Cancer: Changes Over Time and Prognostic Significance
    Seung Yeop Oh, Jaesung Heo, O Kyu Noh, Mison Chun, Oyeon Cho, Young-Taek Oh
    Technology in Cancer Research & Treatment.2018;[Epub]     CrossRef
  • Clinical and molecular diagnosis of pathologic complete response in rectal cancer: an update
    Corey Timmerman, Luis R. Taveras, Sergio Huerta
    Expert Review of Molecular Diagnostics.2018; 18(10): 887.     CrossRef
  • Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: a review
    Byong Chul Yoo, Seung-Gu Yeo
    EPMA Journal.2017; 8(1): 61.     CrossRef
  • Peripheral and Tissue Lymphocytes as Predictors of Pathological Response in Locally Advanced Rectal Cancer Post Neoadjuvant Chemoradiotherapy
    Shereen El Shorbagy, Ola M. Elfarargy, Reham A. Salem, Amina M. Elnaggar, Ola A. Harb, Abeer M. Abdelbary, Hassan R. Ashour, Loay M. Gertallah
    Journal of Cancer Therapy.2017; 08(03): 250.     CrossRef
  • Predicting a pathological complete response in rectal cancer
    Sergio Huerta
    Anti-Cancer Drugs.2016; 27(8): 709.     CrossRef
  • The neutrophil to albumin ratio as a predictor of pathological complete response in rectal cancer patients following neoadjuvant chemoradiation
    Bernard Tawfik, Ali A. Mokdad, Prachi M. Patel, Hsiao C. Li, Sergio Huerta
    Anti-Cancer Drugs.2016; 27(9): 879.     CrossRef
  • Nodal tumor response according to the count of peripheral blood lymphocyte subpopulations during preoperative chemoradiotherapy in locally advanced rectal cancer
    Jaesung Heo, Young-Taek Oh, O Kyu Noh, Mison Chun, Jun-Eun Park, Sung-Ran Cho
    Radiation Oncology Journal.2016; 34(4): 305.     CrossRef
  • Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer
    Oyeon Cho, Young-Taek Oh, Mison Chun, O Kyu Noh, Hyun-Woo Lee
    Tumor Biology.2016; 37(1): 971.     CrossRef
  • The effect of 5-fluorouracil/leucovorin chemotherapy on CpG methylation, or the confounding role of leukocyte heterogeneity: An illustration
    Mathieu Lemire, Syed H.E. Zaidi, Brent W. Zanke, Steven Gallinger, Thomas J. Hudson, Sean P. Cleary
    Genomics.2015; 106(6): 340.     CrossRef
  • 13,642 View
  • 112 Download
  • 29 Web of Science
  • 30 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP